Beyond symptomatic treatment: PDE5 inhibitors as initiators, enablers, and sustainers of erectile function
{{output}}
Phosphodiesterase type-5 inhibitors (PDE5i) are widely used as first-line therapy for erectile dysfunction (ED). Traditionally, they have been viewed primarily as symptomatic agents that facilitate erections during sexual activity. However, extensive clinical ... ...
